Spyre Therapeutics SYRE Growth Metrics (2015-2026)

NASDAQ SYRE
$88.03 +0.78 (+0.89%)
As of: Sep 4, 2026 · 2:26 PM EDT
Reported Financials

Spyre Therapeutics Quarterly Growth Metrics

Periods 44 quarters
Latest Jun 2026

Spyre Therapeutics growth metrics data for the quarter ended Jun 2026. These growth metrics cover 44 quarters of results from Sep 2015 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Growth Metrics Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Growth Ratios
EBITDA Margin Growth (1y)
-0.35M-1.06M-1.08M-0.77M-1.96M
EBITDA Margin Growth (3y)
EBITDA Margin Growth (5y)
0.04M-0.01M-0.11M-0.31M-1.01M-1.10M-0.90M-2.27M
EBITDA Margin (QoQ)
-0.01M-0.04M-0.12M-0.18M-0.72M-0.06M0.19M-1.36M
EBIT Margin Growth (1y)
-0.35M-1.06M-1.08M-0.77M-1.96M
EBIT Margin Growth (3y)
EBIT Margin Growth (5y)
0.04M-0.01M-0.11M-0.31M-1.01M-1.10M-0.90M-2.27M
EBIT Margin (QoQ)
-0.01M-0.04M-0.12M-0.18M-0.72M-0.06M0.19M-1.36M
EBT Margin Growth (1y)
-0.35M-1.04M-1.06M-0.75M-2.80M
EBT Margin Growth (3y)
EBT Margin Growth (5y)
0.04M-0.01M-0.12M-0.31M-1.00M-1.07M-0.88M-3.11M
EBT Margin (QoQ)
-0.01M-0.04M-0.12M-0.18M-0.70M-0.06M0.19M-2.22M
FCF Margin Growth (1y)
-0.33M-0.85M-1.03M-0.70M0.09M
FCF Margin Growth (3y)
FCF Margin Growth (5y)
0.04M-0.02M-0.14M-0.29M-0.81M-1.04M-0.84M-0.20M
FCF Margin (QoQ)
-0.02M-0.04M-0.14M-0.14M-0.54M-0.21M0.19M0.65M
Net Margin Growth (1y)
-0.35M-1.03M-1.06M-0.75M-2.80M
Net Margin Growth (3y)
Net Margin Growth (5y)
0.04M-0.01M-0.12M-0.31M-0.99M-1.08M-0.88M-3.11M
Net Margin (QoQ)
-0.01M-0.04M-0.12M-0.18M-0.69M-0.07M0.19M-2.22M
Operating Margin Growth (1y)
-0.35M-1.06M-1.08M-0.77M-1.96M
Operating Margin Growth (3y)
Operating Margin Growth (5y)
0.04M-0.01M-0.11M-0.31M-1.01M-1.10M-0.90M-2.27M
Operating Margin (QoQ)
-0.01M-0.04M-0.12M-0.18M-0.72M-0.06M0.19M-1.36M
Return on Assets [ROA] Growth (1y)ROA Growth (1y)
-52.00-375.00-0.00M-0.00M-0.00M-0.00M-0.01M-0.01M-0.00M-0.00M0.00M0.01M0.01M0.01M0.01M296.000.00M0.00M0.00M0.00M
Return on Assets [ROA] Growth (3y)ROA Growth (3y)
-129.00488.00-0.00M-0.00M-0.00M-0.00M-0.00M-0.01M-0.01M-0.01M-0.00M208.00-84.000.00M0.00M0.01M0.01M0.01M0.01M0.02M
Return on Assets [ROA] Growth (5y)ROA Growth (5y)
-0.00M-0.00M-0.00M-0.01M-0.00M-0.01M-0.01M-0.01M-0.01M-0.01M-0.00M0.00M0.00M0.00M0.01M0.00M0.00M0.00M0.00M0.00M
Return on Assets [ROA] (QoQ)ROA (QoQ)
-695.00-575.00-0.00M-0.00M599.00-0.00M-0.00M-0.01M0.01M724.000.00M0.00M-987.00973.00494.00-185.00876.00435.0093.00480.00
Return on Capital Employed [ROCE] Growth (1y)ROCE Growth (1y)
-404.00-877.00-0.00M-0.01M-0.00M-0.01M-0.01M0.04M-0.00M0.00M0.01M-0.03M0.01M0.01M0.00M-950.00714.00929.000.00M0.00M
Return on Capital Employed [ROCE] Growth (3y)ROCE Growth (3y)
-370.00466.00-0.00M-0.01M-0.00M-0.00M-0.00M0.03M-0.01M-0.00M-0.00M0.00M573.000.00M0.00M0.01M0.01M0.01M0.01M-0.03M
Return on Capital Employed [ROCE] Growth (5y)ROCE Growth (5y)
-0.00M-0.00M-0.01M-0.01M-0.01M-0.01M-0.01M0.03M-0.01M-0.00M-0.00M0.00M0.00M0.01M0.01M0.00M884.000.00M0.00M0.00M
Return on Capital Employed [ROCE] (QoQ)ROCE (QoQ)
-895.00-827.00-0.00M-0.00M513.00-0.00M-0.00M0.04M-0.04M0.00M0.00M0.00M-0.00M681.00392.00-367.008.00896.00657.00716.00
Return on Invested Capital [ROIC] Growth (1y)ROIC Growth (1y)
-0.02M-0.10M0.01M0.00M950.000.00M
Return on Invested Capital [ROIC] (QoQ)ROIC (QoQ)
0.08M-0.11M0.01M572.00639.00649.00-62.00-276.00871.00
Return on Sales [ROS] Growth (1y)ROS Growth (1y)
-0.35M-1.06M-1.08M-0.77M-1.96M-0.97M-1.59M-2.99M
Return on Sales [ROS] Growth (3y)ROS Growth (3y)
0.05M0.06M0.05M
Return on Sales [ROS] Growth (5y)ROS Growth (5y)
0.04M-0.01M-0.11M-0.31M-1.01M-1.10M-0.90M-2.27M-1.98M-2.62M-3.71M
Return on Sales [ROS] (QoQ)ROS (QoQ)
-0.01M-0.04M-0.12M-0.18M-0.72M-0.06M0.19M-1.36M0.27M-0.69M-1.21M